Business Wire
14 Jun 2026, 19:30 UTC · 10h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
OrsoBio reported positive Phase 2a clinical data for its LXR inverse agonist TLC-2716 in treating SHTG and MASLD. — Positive Phase 2a results are a significant clinical milestone that de-risk the asset and increase the probability of success for future pivotal trials.
+0.60Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Search tags
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
16h ago
